A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
Katharine A. Collier, Hugo E. Valencia, Herbert B. Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, Sophia G. Liva, Christopher C. Coss, Jiang Wang, Soun Khountham, Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling, Amir Mortazavi
Topics & Concepts
MedicineNeurofibromatosis type 2Internal medicineTolerabilityNauseaResponse Evaluation Criteria in Solid TumorsAdverse effectOncologyCancerGastroenterologyPhases of clinical researchSurgeryClinical trialNeurofibromatosisPathologyHistone Deacetylase Inhibitors ResearchNeurofibromatosis and Schwannoma CasesAdrenal and Paraganglionic Tumors